GSK1995057 / GSK - LARVOL DELTA

Immunogenicity and humanization of single-domain antibodies. (PubMed, FEBS J) - "While most clinical trials have demonstrated minimal sdAb immunogenicity, two notable exceptions (the tetrameric DR5-specific V H TAS266 and the TNFR1-specific V GSK1995057) illustrate that special caution must be taken in identifying pre-existing ADAs against highly potent sdAbs...Whether sdAb humanization reduces or promotes immunogenicity remains unclear: reduction of non-human sequence content at the expense of introducing low-level aggregation in humanized variants may be counterproductive. Further work will establish thresholds for V H and V humanization to maximize human sequence content while avoiding loss of binding affinity and/or immunogenicity resulting from aggregation or decreased stability."

Journal • Review • IGH

Inhibition of TNFR1 Attenuates LPS Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Regulating the NF-KB and MAPK Signalling Pathway. (PubMed, Neurochem Res) - "The aim of this study was to investigate the potential therapeutic effect of TNFR1 siRNA and selective antagonists of TNFR1 (GSK1995057) on HNPC damage...In summary, the blockade of TNFR1 effectively suppressed LPS-induced apoptosis and inflammation in HNPCs through the NF-KB and MAPK signalling pathways. This revealed that the blockade of TNFR1 may provide a potential therapeutic treatment for IDD."

Journal • Immunology • Inflammation

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057 (clinicaltrials.gov) - P1; N=53; Completed; Sponsor: GlaxoSmithKline; N=108 ➔ 53

Clinical • Enrollment change

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057 (clinicaltrials.gov) - P1; N=53; Completed; Sponsor: GlaxoSmithKline

Clinical • New P1 trial

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057 (clinicaltrials.gov) - P1; N=53; Completed; Sponsor: GlaxoSmithKline; Recruiting ➔ Completed

Clinical • Trial completion